STOCK TITAN

Celcuity (CELC) 10-K Filings

CELC NASDAQ

Here are the 10-K annual reports from Celcuity Inc. (CELC) in our archive since June 2025, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.

A 10-K covers the audited annual report, with the full financial statements, so if you follow CELC and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full CELC filings page.

Rhea-AI Summary

Celcuity Inc. is a clinical-stage biotech focused on targeted therapies for solid tumors, led by its pan‑PI3K/mTOR inhibitor gedatolisib for HR+/HER2‑ advanced breast cancer and metastatic castration‑resistant prostate cancer. More than 1,100 people have received gedatolisib across completed and ongoing trials.

The Phase 3 VIKTORIA‑1 breast cancer trial enrolled 754 patients and showed that gedatolisib triplet and doublet regimens delivered large, statistically significant progression‑free survival benefits versus fulvestrant, including in PIK3CA wild‑type tumors. Gedatolisib has Fast Track and Breakthrough Therapy designations, is under Real‑Time Oncology Review, and its NDA has Priority Review with a July 17, 2026 PDUFA goal date.

Celcuity estimates a U.S. second‑line breast cancer market opportunity of more than $5.0 billion annually and potential peak revenue up to $2.5 billion if approved for both PIK3CA wild‑type and mutant populations. The company licenses gedatolisib from Pfizer, with up to $335.0 million in potential milestones and low‑ to mid‑teen royalties.